Source comparison
Thymosin Alpha-1 Help MS Research: Study Type Comparison
EAE Animal Model (2017) C57BL/6 mice, MOG-induced EAE Clinical severity score, histological infiltration 100 μg subcutaneous twice weekly 45% reduction in spinal cord T-cell infiltrates, delayed peak severity Strong mechanistic evidence in acute inflammation m
This comparison does not assign a generated winner or score.
- EAE Animal Model (2017)
- C57BL/6 mice, MOG-induced EAE
- Clinical severity score, histological infiltration
- 100 μg subcutaneous twice weekly
- 45% reduction in spinal cord T-cell infiltrates, delayed peak severity
- Strong mechanistic evidence in acute inflammation model; doesn't address chronic progressive disease
- Human Pilot (2018)
- 24 RRMS patients, 12-week trial
- Gadolinium-enhancing lesions on MRI
- 1.6mg subcutaneous twice weekly
- 28% reduction in active lesions vs baseline; no change in EDSS or relapse rate
- Demonstrates immune activity in humans but lacks functional clinical benefit within trial window
- Combination Study (2020)
- 56 RRMS patients, 24-month observational
- Annualized relapse rate
- 1.6mg subcutaneous twice weekly + IFN-β-1b
- 0.32 relapses/year vs 0.58 with IFN alone
- Methodologically limited (no blinding, heterogeneous baselines); requires independent replication
- Cytokine Analysis (2019)
- EAE rats, pre-treatment protocol
- Serum IL-17, TNF-α, Treg frequency
- 200 μg intraperitoneal daily × 10 days
- 40% increase in Treg frequency, 32% reduction in Th17 cells
- Confirms T-cell phenotype shift; unclear if dose translates to human protocols